OpenScience.ink

3 weeks ago • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

GLP-1 receptor drugs linked to lower kidney cancer risk after weight-loss surgeryGLP-1 receptor agonists are associated with lower kidney cancer risk after metabolic bariatric surgery.

🎖️ Top 10% JournalArticle

3 weeks ago • Endocrinology

Key roles of a β-cell protein and sex in controlling α-cell shape and functionβ-cell 14-3-3-ζ and sex are key regulators of α-cell form and function.

🎖️ Top 10% JournalArticle

3 weeks ago • Clinical medicine insights. Endocrinology and diabetes

Real-World Comparison of GLP-1RA and SGLT2-Inhibitor Treatment Versus Standard CareReal-World Evidence of the GLP-1RA/SGLT2-i Therapy versus Standard Care: A Retrospective Cohort Study.

📖 Top 30% JournalArticle

3 weeks ago • Obesity (Silver Spring, Md.)

Effectiveness and Safety of GLP-1 Medicines for Patients Who Regain Weight After Weight-Loss SurgeryReal-World Effectiveness and Safety of GLP-1 Receptor Agonists Among Patients With Weight Recurrence After Bariatric Surgery.

🎖️ Top 10% JournalArticle

3 weeks ago • Obesity pillars

One-year weight loss and metabolism changes after sleeve stomach surgery in teens compared with young adultsOne-year weight loss and metabolic outcomes after laparoscopic sleeve gastrectomy in adolescents compared with young adults: A propensity score-matched cohort study.

📖 Top 20% JournalArticle

3 weeks ago • The Laryngoscope

Hair Loss Without Scarring in Adults Using GLP-1 Medications: A Matched Group StudyNonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study.

Article

3 weeks ago • Journal of personalized medicine

Health outcomes linked to GLP-1 receptor drugs in non-diabetic patients with long-term pancreatitisClinical Outcomes Associated with GLP-1 Receptor Agonist Exposure in Non-Diabetic Patients with Chronic Pancreatitis: A Retrospective Cohort Study.

📖 Top 20% JournalArticle

3 weeks ago • Science advances

Designing long-lasting and brain-stable GLP-1 receptor drugs based on how IDE breaks down GLP-1IDE-mediated GLP-1 degradation as the basis for designing long-acting and CNS-stable GLP-1 receptor agonists.

🥈 Top 2% JournalArticle

3 weeks ago • Food & function

Non-digestible stachyose may reverse insulin resistance caused by overeating by boosting a hormone that regulates blood sugarNon-digestible stachyose reverses overnutrition-induced insulin resistance via stimulating the secretion of glucagon-like peptide-1.

📖 Top 20% JournalArticle

3 weeks ago • JAMA psychiatry

Glucagon-Like Peptide 1 Drugs, Death Rates, and Heart Health in Serious Mental IllnessGlucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.

🥇 Top 1% JournalArticle

3 weeks ago • Diabetes, obesity & metabolism

Heart and kidney risks and safety of GLP-1 medicines in type 2 diabetes patients with BMI under 27Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation.

Article

3 weeks ago • The American journal of managed care

Changes in Semaglutide Prescriptions After New FDA and Medicare RulesChanges in Semaglutide Fills Following Expanded FDA and Medicare Policies.

📖 Top 30% JournalArticle

3 weeks ago • Pulmonology

Use and unmet needs of GLP-1 drugs in sleep medicine across Europe: A survey from the sleep apnea networkClinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network.

🎖️ Top 10% JournalMulticenter Study

3 weeks ago • Physiology & behavior

How Glucagon-Like Peptide-1 Receptor Agonists Affect Taste and Eating BehaviorThe Effects of Glucagon-Like Peptide-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior.

Article

3 weeks ago • Cureus

When Weight Loss Becomes Harmful: Ketoacidosis Linked to Tirzepatide in a Woman Without DiabetesWhen Weight Loss Turns Dangerous: A Case Report of Tirzepatide-Induced Ketoacidosis in a Non-diabetic Woman.

Case Reports

3 weeks ago • Obesity facts

Changes in Body Fat, Metabolism, and Muscle Strength Over Time in People with Obesity Taking SemaglutideLongitudinal Changes in Body Composition, Adaptive Thermogenesis and Muscle Strength in Patients with Obesity Treated with Semaglutide.

🎖️ Top 10% JournalArticle

3 weeks ago • International journal of women's dermatology

Medical weight management’s effects on appearance, muscle, and skin based on patient reports to guide overall preventionAesthetic, muscle, and dermatologic effects of medical weight management: patient-reported outcomes shape a holistic preventive procedural approach.

📖 Top 30% JournalArticle

3 weeks ago • Cureus

Comparing heart-related side effects of Semaglutide and Tirzepatide using FDA safety reports from 2022 to 2026Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026).

Article

3 weeks ago • Parkinsonism & related disorders

How GLP-1 slows stomach emptying and affects levodopa absorption in Parkinson's disease: Clinical significanceGLP-1-mediated delay in gastric emptying and impact on levodopa absorption in Parkinson's disease: Clinical implications.

Article

3 weeks ago • BMJ open

Effectiveness and safety of diabetes drugs that activate GLP-1 receptors for heart muscle disease in diabetesEfficacy and safety of glucagon-like peptide-1 receptor agonists for diabetic cardiomyopathy: a protocol for systematic review and meta-analysis.

📖 Top 20% JournalArticle

3 weeks ago • MedComm

Metabolic Syndrome: Causes and Possible TreatmentsMetabolic Syndrome: From Mechanisms to Therapeutic Interventions.

🥉 Top 5% JournalArticle

3 weeks ago • Clinical journal of the American Society of Nephrology : CJASN

Use of Glucagon-Like Peptide-1 Drugs and Risks of Hospital Stay and Death in People with Advanced Kidney DiseaseGlucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease.

🥉 Top 5% JournalArticle

3 weeks ago • Diabetes, obesity & metabolism

Changes in Healthcare Costs for Adults Over 55 with Obesity or Overweight Using Tirzepatide Without DiabetesTrends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis.

Article

← prevpage 12 of 14next →

Latest GLP-1 Therapies Research Papers